Clinical and biological implications of Hippo pathway dysregulation in sarcomas Cover

.blurhash-client-img { display: none !important; }

Clinical and biological implications of Hippo pathway dysregulation in sarcomas

Forum of Clinical Oncology

Volume 9 (2018): Issue 1 (December 2018)

By: Anastasios Kyriazoglou, Roubini Zakopoulou, Flora Zagouri, Aristotelis Bamias and Meletios Athanasios Dimopoulos

Open Access

|Jul 2019

Authors

Anastasios Kyriazoglou

tassoskyr@gmail.com

Department of Clinical Therapeutics, General Hospital Alexandra, Athens, Greece

Roubini Zakopoulou

Department of Clinical Therapeutics, General Hospital Alexandra, Athens, Greece

Flora Zagouri

Department of Clinical Therapeutics, General Hospital Alexandra, Athens, Greece

Aristotelis Bamias

Department of Clinical Therapeutics, General Hospital Alexandra, Athens, Greece

Meletios Athanasios Dimopoulos

Department of Clinical Therapeutics, General Hospital Alexandra, Athens, Greece

DOI: https://doi.org/10.2478/fco-2018-0002 | Journal eISSN: 1792-362X | Journal ISSN: 1792-345X

Journal RSS Feed

Language: English

Page range: 11 - 16

Submitted on: Sep 24, 2018

|

Accepted on: Feb 28, 2019

|

Published on: Jul 12, 2019

Published by: Helenic Society of Medical Oncology

In partnership with: Paradigm Publishing Services

Publication frequency: 2 issues per year

Keywords:

Related subjects:

Clinical medicine,

Internal medicine,

Haematology, oncology

© 2019 Anastasios Kyriazoglou, Roubini Zakopoulou, Flora Zagouri, Aristotelis Bamias, Meletios Athanasios Dimopoulos, published by Helenic Society of Medical Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Previous article Volume 9 (2018): Issue 1 (December 2018)Next article